bioRxiv preprint doi: https://doi.org/10.1101/2021.05.26.445708; this version posted May 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. The P5-ATPase ATP13A1 modulates MR1- mediated antigen presentation Corinna A. Kulicke1, Erica De Zan2, Zeynep Hein3, Claudia Gonzalez-Lopez1, Swapnil Ghanwat3, Natacha Veerapen4, Gurdyal S. Besra4, Paul Klenerman5,6, John C. Christianson7, Sebastian Springer3, Sebastian Nijman2, Vincenzo Cerundolo1, #, § , and Mariolina Salio1, # 1. MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK 2. Ludwig Institute for Cancer Research Ltd. and Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK 3. Department of Life Sciences and Chemistry, Jacobs University, Bremen, Germany. 4. School of Biosciences, University of Birmingham, Birmingham B11 2TT, United Kingdom 5. Peter Medawar Building, Nuffield Department of Medicine, University of Oxford 6. Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford 7. Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK # joint senior authors § deceased January 7th 2020 current addresses: C.K. – Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, United States; S.N. – Scenic Biotech BV, Amsterdam, The Netherlands correspondence:
[email protected];
[email protected] Keywords: MHC I-related protein 1 (MR1), mucosal-associated invariant T cell (MAIT), MR1-restricted T cell (MR1T), antigen presentation, protein trafficking, HAP1, gene trap, ATP13A1, P5-type ATPase bioRxiv preprint doi: https://doi.org/10.1101/2021.05.26.445708; this version posted May 27, 2021.